148. Back to Basics - Metastatic Triple Positive (HER2) Breast Cancer

As our breast cancer journey comes close to finishing, it was always the destiny of your cohost's on Oncology for the Inquisitive Mind to talk about HER2-positive breast cancer. This week, we target both antibody-drug conjugate therapy and targeted therapy (trastuzumab deruxtecan and pertuzumab). While HER2-positive cancer's survival is one of the best for metastatic disease, this was not always the case. Studies discussed in the episode: DESTINY 03 CLEOPATRA Trial For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.